Login to Access Video or Poster Abstract: MP56-03
Sources of Funding: None

Introduction

To examine the change in penile vascular parameters after administration of collagenase Clostridium Histolyticum (CCH) in patients with Peyronie&[prime]s disease (PD).

Methods

We conducted a retrospective review of the records for a cohort of collagenase patients treated with CCH for PD between 04/2014 and 03/2016 who underwent penile duplex Doppler ultrasound (PDDU) after pharmacologically induced erection both before and after CCH treatment. The primary outcomes measured were changes in peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (RI) after CCH treatment. Paired t-Tests were performed to determine statistical significance (P<0.05).

Results

A total of 24 patients were included in the study, of which 20 (83%) completed four cycles of treatment (consisting of eight total injections) and 4 completed three cycles. After 3-4 cycles of CCH therapy, there was no statistically significant change in EDV, RI, or International Index of Erectile Function (IIEF) score when compared to baseline. PSV, however, improved significantly from 48.4±11.9 cm/s at baseline to 52±10.9 cm/s (p<0.05) after CCH therapy. There was also a statistically significant change in penile curvature (56.5±18.7° to 34.7±18.1°, p<0.001) and erect penile circumference (11.5±1.2 cm to 11.9±1.3 cm, p<0.05) after treatment.

Conclusions

In spite of a significant change in penile curvature, this change did not correlate with changing penile vascular parameters. There was a significant increase in PSV after completion of CCH therapy, although this change did not translate into improved subjective erectile function. However, as suggested by the lack of change in EDV and RI before and after treatment, as well as the absence of any clinical correlation with PSV, EDV, or RI, CCH therapy likely has a negligible impact on penile vasculature, further supporting a favorable safety profile of CCH.

Funding

None